Mirati Therapeutics Inc

Open

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-0.05% downside

Nieuwssentiment

By Acuity

100%

0%

316 / 342 Rangschikking in Healthcare

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 jun 2026, 23:36 UTC

News
Social Media

MercadoLibre Inc. shares declined in after-market trading following news of a securities fraud investigation related to loan term disclosures, raising investor concerns.

30 jun 2026, 23:36 UTC

News
Correlated Moves
Macro News
ETF Constituents

Vanguard Information Technology ETF's performance has been roughly flat during after-market hours, following a positive environment for technology stocks and the Nasdaq's rebound.

30 jun 2026, 23:26 UTC

News
Correlated Moves

iShares iBoxx $ Investment Grade Corporate Bond ETF trades lower in after-market hours, amid a broader decline in U.S. equity indices and technology stocks.

30 jun 2026, 23:21 UTC

News
Social Media

Micron Technology shares rose after hours, buoyed by a $250 million investment and significant revenue growth linked to AI chipmakers.

30 jun 2026, 23:11 UTC

News

Comcast Corp shares rose in after-market trading, continuing an upward trend. The company's market cap now exceeds that of American Tower, ranking 135th in the S&P 500.

30 jun 2026, 23:06 UTC

News
Correlated Moves

The US 10Y Treasury Bond Index is near unchanged in after-market hours, following a slight increase earlier in the day. The iShares 7-10 Year Treasury Bond ETF mirrors this stability.

30 jun 2026, 23:06 UTC

Social Media
News

Microsoft shares rise in after-market hours, driven by strength in the Systems Software sub-sector and a new partnership with Chevron for a natural gas facility.

30 jun 2026, 23:02 UTC

Social Media
News

Tesla Inc. shares are lower in after-market hours following Michael Burry's short position disclosure and a fatal incident involving one of its vehicles.

30 jun 2026, 23:02 UTC

News

The iShares 20+ Year Treasury Bond ETF is lower in after-market trading, reflecting broader declines in U.S. indices and mixed market conditions.

30 jun 2026, 23:02 UTC

News
ETF Constituents

Vanguard Growth ETF declines in after-market trading, driven by losses in top holdings NVIDIA, Tesla, and Meta, despite slight gains in the Nasdaq 100 Index.

30 jun 2026, 23:01 UTC

News

Fox Corp has secured a $1 billion loan to fund its Roku acquisition. Shares are higher in after-market hours, aided by a strong Broadcasting sector.

30 jun 2026, 22:51 UTC

News

Vanguard Total Bond Market ETF is lower in after-market hours, reflecting broader market pullbacks amid geopolitical tensions and fluctuating oil prices.

30 jun 2026, 20:08 UTC

News
Correlated Moves

Ethereum is trading lower, influenced by Bitcoin's decline. Sharplink's acquisition of 10,000 ETH at $1,611 has not prevented the drop.

30 jun 2026, 20:07 UTC

News

Vertex Pharmaceuticals is trading lower amid broader market pressures despite promising first-quarter results. Earlier in the session, shares briefly reached a high before declining.

30 jun 2026, 20:07 UTC

Social Media
News

Intel Corp shares are advancing, driven by bullish semiconductor activity and increased buying interest. The stock reached a post-alert high of $131.14.

30 jun 2026, 20:07 UTC

News
Correlated Moves
Social Media

NVIDIA shares rose following SemiAnalysis's bullish projection for data center revenue, expected to exceed consensus by 20% in fiscal 2027's second half.

30 jun 2026, 20:07 UTC

News
Correlated Moves

Ethereum is trading lower, influenced by Bitcoin's decline and broader market pressures. Earlier, it dipped to a session low of $1,611.

30 jun 2026, 20:03 UTC

News
Correlated Moves
Social Media

Apple Inc. shares are higher after the Supreme Court agreed to hear its appeal in the Epic Games antitrust case, potentially benefiting App Store fees.

30 jun 2026, 20:03 UTC

News
Correlated Moves
Social Media

Analyst raises AMD price target to $615, citing strong AI demand. Shares are trading higher since Monday, reflecting positive market sentiment.

30 jun 2026, 20:03 UTC

Social Media
Correlated Moves
ETF Constituents
News

Invesco QQQ Trust Series I advances today, driven by positive technology sector sentiment and strong performance from major contributors like AMD and Apple.

30 jun 2026, 20:03 UTC

News
ETF Constituents

Health Care Select Sector SPDR Fund declines as health care underperforms, with Eli Lilly and Stryker contributing to the negative performance during Tuesday's session.

30 jun 2026, 20:03 UTC

Correlated Moves
News
ETF Constituents

Germany's retail sales rose 1.1% in May, exceeding expectations. The iShares MSCI Germany ETF is gaining, supported by strong performances from key holdings.

30 jun 2026, 20:02 UTC

Correlated Moves
Social Media
News

Applied Materials shares are higher today following price target increases, including Susquehanna's raise to $900 from $575, reflecting strong analyst sentiment.

30 jun 2026, 20:01 UTC

News

Expedia Group Inc shares are lower today amid a decline in the Hotels, Resorts & Cruise Lines sector. Wells Fargo cut its price target to $303.

30 jun 2026, 20:01 UTC

News

ASML Holding NV shares are higher amid positive sentiment and Bernstein's price target increase, supported by $518 billion in semiconductor infrastructure investments.

30 jun 2026, 20:01 UTC

News
Correlated Moves

Intuitive Surgical shares are lower, reaching a four-week low amid declines in the Health Care Equipment sub-sector and volatility in the market.

30 jun 2026, 20:01 UTC

News
Social Media

Illumina Inc shares are lower as Roche launches a competing gene sequencer at a lower price, challenging Illumina's market share in genetic testing technology.

30 jun 2026, 19:56 UTC

News

Henry Schein announced a partnership with GoTu Technology to enhance dental workforce support, though shares are lower during Tuesday's session.

30 jun 2026, 19:56 UTC

News
Correlated Moves

Concerns over currency volatility arise as the yen weakens against the dollar. EUR/HKD remains roughly flat since Monday's close amid broader market dynamics.

30 jun 2026, 19:52 UTC

News

Costco Wholesale shares are lower, reaching a four-week low of $938.50, amid declines in the Consumer Staples Merchandise Retail sub-sector.

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD  -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

0

Buy

5

Hold

0

Sell

Sentiment

By Acuity

316 / 342 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

$

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
help-icon Live chat